 Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsedrefractory multiple myeloma to be presented in a poster at ASH on Sunday, December 11, 2022, from 6:00 p.m. 8:00 p.m. CT Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsedrefractory multiple myeloma to be presented in a poster at ASH on Sunday, December 11, 2022, from 6:00 p.m. 8:00 p.m. CT 